PATENT CLAIM ANALYSIS

Application Number: 16364463
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "289000"]

Abstract:
Described herein are dosage forms of enantiomerically enriched (S)-bupropion or enantiomerically enriched (R)-bupropion. The (S)-bupropion or the (R)-bupropion may be deuterium enriched, or may have natural isotopic abundance. These dosage forms may be administered, either fed or fasted, to treat a condition recited herein, to achieve a certain pharmacokinetic parameter of a bupropion or a metabolite of a bupropion, and/or to enhance dextromethorphan plasma levels.

Claim (Index 6):
The method of  claim 5 , wherein administering the dosage form results in a combined C max  of (S)-bupropion and (R)-bupropion, on day 8, that is at least about 100 ng/mL.

Metadata:
- Claim Count in Document: 68.0
- Percentile: 99.0
- Lexical Diversity: 1.84783
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14997316', '15164767', '15130807', '15599163', '14617624']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8559694028920667
- 35 USC 102 Novelty (BERT): 0.545925233953244
- Combined Prediction Score: 0.8249649859981845
- Mean Citation Score: 445.30945200000014
- Max Citation Score: 450.97195
- Similarity Product: 297.94010900142194

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test